Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Formation of protein sub-visible particles during vacuum degassing of etanercept solutions.

Wang H, Zheng HJ, Wang Z, Bai H, Carpenter JF, Chen S, Fang WJ.

Int J Biol Macromol. 2014 May;66:151-7. doi: 10.1016/j.ijbiomac.2014.02.001.

PMID:
24513220
2.

Comparison of analytical methods to detect instability of etanercept during thermal stress testing.

Maarschalkerweerd Av, Wolbink GJ, Stapel SO, Jiskoot W, Hawe A.

Eur J Pharm Biopharm. 2011 Jun;78(2):213-21. doi: 10.1016/j.ejpb.2011.01.012.

PMID:
21272639
3.

Comprehensive evaluation of etanercept stability in various concentrations with biophysical assessment.

Kim NA, Lim DG, Lim JY, Kim KH, Jeong SH.

Int J Pharm. 2014 Jan 2;460(1-2):108-18. doi: 10.1016/j.ijpharm.2013.11.019.

PMID:
24269208
4.

Protein spray-freeze drying. Effect of atomization conditions on particle size and stability.

Costantino HR, Firouzabadian L, Hogeland K, Wu C, Beganski C, Carrasquillo KG, Córdova M, Griebenow K, Zale SE, Tracy MA.

Pharm Res. 2000 Nov;17(11):1374-83.

PMID:
11205730
5.

Enhanced aqueous dissolution of a poorly water soluble drug by novel particle engineering technology: spray-freezing into liquid with atmospheric freeze-drying.

Rogers TL, Nelsen AC, Sarkari M, Young TJ, Johnston KP, Williams RO 3rd.

Pharm Res. 2003 Mar;20(3):485-93.

PMID:
12669973
6.

Evaluation of etanercept stability as exposed to various sugars with biophysical assessment.

Lim DG, Kim NA, Lim JY, Kim KH, Hada S, Jeong SH.

Int J Pharm. 2014 Dec 10;476(1-2):50-9. doi: 10.1016/j.ijpharm.2014.09.037.

PMID:
25269011
7.

Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.

Schüle S, Friess W, Bechtold-Peters K, Garidel P.

Eur J Pharm Biopharm. 2007 Jan;65(1):1-9.

PMID:
17034996
8.

How subvisible particles become invisible-relevance of the refractive index for protein particle analysis.

Zölls S, Gregoritza M, Tantipolphan R, Wiggenhorn M, Winter G, Friess W, Hawe A.

J Pharm Sci. 2013 May;102(5):1434-46. doi: 10.1002/jps.23479.

PMID:
23463514
9.

Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems.

Mattern M, Winter G, Kohnert U, Lee G.

Pharm Dev Technol. 1999 May;4(2):199-208.

PMID:
10231881
10.

Protein inhalation powders: spray drying vs spray freeze drying.

Maa YF, Nguyen PA, Sweeney T, Shire SJ, Hsu CC.

Pharm Res. 1999 Feb;16(2):249-54.

PMID:
10100310
11.

Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.

Nishi H, Mathäs R, Fürst R, Winter G.

J Pharm Sci. 2014 Jan;103(1):90-9. doi: 10.1002/jps.23782.

PMID:
24218205
12.

Effect of spray drying and subsequent processing conditions on residual moisture content and physical/biochemical stability of protein inhalation powders.

Maa YF, Nguyen PA, Andya JD, Dasovich N, Sweeney TD, Shire SJ, Hsu CC.

Pharm Res. 1998 May;15(5):768-75.

PMID:
9619788
13.

Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags.

Kumru OS, Liu J, Ji JA, Cheng W, Wang YJ, Wang T, Joshi SB, Middaugh CR, Volkin DB.

J Pharm Sci. 2012 Oct;101(10):3636-50. doi: 10.1002/jps.23224.

PMID:
22733600
14.

Distinct effects of sucrose and trehalose on protein stability during supercritical fluid drying and freeze-drying.

Jovanović N, Bouchard A, Hofland GW, Witkamp GJ, Crommelin DJ, Jiskoot W.

Eur J Pharm Sci. 2006 Mar;27(4):336-45.

PMID:
16338123
15.

Thermal ink-jet spray freeze-drying for preparation of excipient-free salbutamol sulphate for inhalation.

Mueannoom W, Srisongphan A, Taylor KM, Hauschild S, Gaisford S.

Eur J Pharm Biopharm. 2012 Jan;80(1):149-55. doi: 10.1016/j.ejpb.2011.09.016.

PMID:
22001519
16.

Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods.

Werk T, Volkin DB, Mahler HC.

Eur J Pharm Sci. 2014 Mar 12;53:95-108. doi: 10.1016/j.ejps.2013.12.014.

PMID:
24370624
17.

Pharmaceutical feasibility of sub-visible particle analysis in parenterals with reduced volume light obscuration methods.

Hawe A, Schaubhut F, Geidobler R, Wiggenhorn M, Friess W, Rast M, de Muynck C, Winter G.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):1084-7. doi: 10.1016/j.ejpb.2013.02.004.

PMID:
23454051
18.

Systematic investigation of the effect of lyophilizate collapse on pharmaceutically relevant proteins III: collapse during storage at elevated temperatures.

Schersch K, Betz O, Garidel P, Muehlau S, Bassarab S, Winter G.

Eur J Pharm Biopharm. 2013 Oct;85(2):240-52. doi: 10.1016/j.ejpb.2013.05.009.

PMID:
23727369
19.

Fundamentals of freeze-drying.

Nail SL, Jiang S, Chongprasert S, Knopp SA.

Pharm Biotechnol. 2002;14:281-360. Review.

PMID:
12189727
20.

The effect of freeze-drying parameters and formulation composition on IgG stability during drying.

Heljo VP, Harju H, Hatanpää T, Yohannes G, Juppo AM.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):752-5. doi: 10.1016/j.ejpb.2013.03.033.

PMID:
23623795
Items per page

Supplemental Content

Support Center